Cargando…
Gene Expression and Protein Abundance of Hepatic Drug Metabolizing Enzymes in Liver Pathology
Hepatic drug metabolizing enzymes (DMEs) markedly affect drug pharmacokinetics. Because liver diseases may alter enzymatic function and in turn drug handling and clinical efficacy, we investigated DMEs expression in dependence on liver pathology and liver failure state. In 5 liver pathologies (hepat...
Autores principales: | Drozdzik, Marek, Lapczuk-Romanska, Joanna, Wenzel, Christoph, Szelag-Pieniek, Sylwia, Post, Mariola, Skalski, Łukasz, Kurzawski, Mateusz, Oswald, Stefan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8471929/ https://www.ncbi.nlm.nih.gov/pubmed/34575411 http://dx.doi.org/10.3390/pharmaceutics13091334 |
Ejemplares similares
-
Protein Abundance of Drug Metabolizing Enzymes in Human Hepatitis C Livers
por: Drozdzik, Marek, et al.
Publicado: (2023) -
Protein Abundance of Drug Transporters in Human Hepatitis C Livers
por: Droździk, Marek, et al.
Publicado: (2022) -
Hepatic drug-metabolizing enzymes and drug transporters in Wilson’s disease patients with liver failure
por: Szeląg-Pieniek, Sylwia, et al.
Publicado: (2021) -
The reference liver—CYP450 and UGT enzymes in healthy donor and metastatic livers: the impact of genotype
por: Kurzawski, Mateusz, et al.
Publicado: (2021) -
Monocarboxylate Transporter 1 (MCT1) in Liver Pathology
por: Droździk, Marek, et al.
Publicado: (2020)